Molly M Jeffery1, Nancy E Morden2,3, Marc Larochelle4, Nilay D Shah1,5, W Michael Hooten6, Ellen Meara2,7. 1. Department of Health Sciences Research, Mayo Clinic, Rochester, MN. 2. Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth College, Lebanon, NH. 3. Microsoft Artificial Intelligence and Research, Healthcare NeXT, Richmond, VA. 4. Section of General Internal Medicine, School of Medicine, Boston University, Boston. 5. OptumLabs, Cambridge, MA. 6. Department of Anesthesiology, Mayo Clinic College of Medicine, Rochester, MN. 7. National Bureau of Economic Research, Cambridge, MA.
Abstract
OBJECTIVE: Experts cautioned that patients affected by the November 2010 withdrawal of the opioid analgesic propoxyphene might receive riskier prescriptions. To explore this, we compared drug receipts and outcomes among propoxyphene users before and aftermarket withdrawal. STUDY DESIGN: Using OptumLabs data, we studied 3 populations: commercial, Medicare Advantage (MA) aged (age 65+ y) and MA disabled (age below 65 y) enrollees. The exposed enrollees received propoxyphene in the 3 months before market withdrawal (n=13,622); historical controls (unexposed) received propoxyphene 1 year earlier (n=9971). Regression models estimated daily milligrams morphine equivalent (MME), daily prescription acetaminophen dose, potentially toxic acetaminophen doses, nonopioid prescription analgesics receipt, emergency room visits, and diagnosed falls, motor vehicle accidents, and hip fractures. PRINCIPAL FINDINGS: Aged MA enrollees illustrate the experience of all 3 populations examined. Following the market withdrawal, propoxyphene users in the exposed cohort experienced an abrupt decline of 69% in average daily MME, compared with a 14% decline in the unexposed. Opioids were discontinued by 34% of the exposed cohort and 18% of the unexposed. Tramadol and hydrocodone were the most common opioids substituted for propoxyphene. The proportion of each group receiving ≥4 g of prescription acetaminophen per day decreased from 12% to 2% in the exposed group but increased from 6% to 8% among the unexposed. Adverse events were rare and not significantly different in exposed versus unexposed groups. CONCLUSIONS: After propoxyphene market withdrawal, many individuals experienced abrupt discontinuation of opioids. Policymakers might consider supporting appropriate treatment transitions and monitoring responses following drug withdrawals.
OBJECTIVE: Experts cautioned that patients affected by the November 2010 withdrawal of the opioid analgesic propoxyphene might receive riskier prescriptions. To explore this, we compared drug receipts and outcomes among propoxyphene users before and aftermarket withdrawal. STUDY DESIGN: Using OptumLabs data, we studied 3 populations: commercial, Medicare Advantage (MA) aged (age 65+ y) and MA disabled (age below 65 y) enrollees. The exposed enrollees received propoxyphene in the 3 months before market withdrawal (n=13,622); historical controls (unexposed) received propoxyphene 1 year earlier (n=9971). Regression models estimated daily milligrams morphine equivalent (MME), daily prescription acetaminophen dose, potentially toxic acetaminophen doses, nonopioid prescription analgesics receipt, emergency room visits, and diagnosed falls, motor vehicle accidents, and hip fractures. PRINCIPAL FINDINGS: Aged MA enrollees illustrate the experience of all 3 populations examined. Following the market withdrawal, propoxyphene users in the exposed cohort experienced an abrupt decline of 69% in average daily MME, compared with a 14% decline in the unexposed. Opioids were discontinued by 34% of the exposed cohort and 18% of the unexposed. Tramadol and hydrocodone were the most common opioids substituted for propoxyphene. The proportion of each group receiving ≥4 g of prescription acetaminophen per day decreased from 12% to 2% in the exposed group but increased from 6% to 8% among the unexposed. Adverse events were rare and not significantly different in exposed versus unexposed groups. CONCLUSIONS: After propoxyphene market withdrawal, many individuals experienced abrupt discontinuation of opioids. Policymakers might consider supporting appropriate treatment transitions and monitoring responses following drug withdrawals.
Authors: Mark J Edlund; Mark A Austen; Mark D Sullivan; Bradley C Martin; James S Williams; John C Fortney; Teresa J Hudson Journal: Pain Date: 2014-08-29 Impact factor: 6.961
Authors: Karen Miotto; Arthur K Cho; Mohamed A Khalil; Kirsten Blanco; Jun D Sasaki; Richard Rawson Journal: Anesth Analg Date: 2017-01 Impact factor: 5.108
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: Corey J Hayes; Teresa J Hudson; Martha M Phillips; Zoran Bursac; James S Williams; Mark A Austin; Mark J Edlund; Bradley C Martin Journal: Pharmacoepidemiol Drug Saf Date: 2015-08-06 Impact factor: 2.890
Authors: Molly Moore Jeffery; W Michael Hooten; Henry J Henk; M Fernanda Bellolio; Erik P Hess; Ellen Meara; Joseph S Ross; Nilay D Shah Journal: BMJ Date: 2018-08-01